Contract manufacturing and specialty revenues boost Jubilant
This article was originally published in Scrip
Executive Summary
Jubilant Organosys has reported an 8.4% jump in revenues to Rs8.96 billion ($183 million) for its first quarter ended June 30th, aided by robust growth in the contract manufacturing and the speciality pharmaceuticals businesses.